ArticleAnnals of surgical oncology2021
Systemic Inflammatory Markers Combined with Tumor-Infiltrating Lymphocyte Density for the Improved Prediction of Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer.
Article in Annals of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Tumour immune microenvironment prognostic factors in locally advanced rectal cancer, a systematic review.Frontiers in oncology · 2025Pooled it
- The role of lymphocyte-C-reactive protein ratio in the prognosis of gastrointestinal cancer: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Integrated model of MRI biomarkers and clinical factors for predicting pathologic response after neoadjuvant chemoradiotherapy in locally advanced rectal cancer.Abdominal radiology (New York) · 2026Article
- Relationship Between the Product of Pre-Treatment Neutrophil and Monocyte Counts and Clinical Outcomes in Rectal Cancer With Suspected Lateral Lymph Node Metastasis.Annals of gastroenterological surgery · 2026Article
- Prognostic significance of integrating pretreatment biopsy-derived Immunoscore and Pan-Immune-Inflammation value in locally advanced rectal cancer after neoadjuvant chemoradiotherapy.Clinical and translational radiation oncology · 2026Article
- The Tumour Immune Microenvironment as a Predictor of the Response to Neoadjuvant Therapy in Rectal Cancer.Cancers · 2026Review
- Dynamic variation in a combined inflammation-tumor marker index during neoadjuvant chemotherapy and its value for organ-preservation decisions in gastric cancer.Open life sciences · 2026Article
- Inflammation-immune-nutrition biomarkers and PSA variability: A population-based study on the clinical potential of the CALLY index.Biomedical reports · 2025Article
- Role of neutrophil-to-lymphocyte, platelet-to-lymphocyte, and monocyte-to-lymphocyte ratios in rectal cancer prognosis.World journal of gastrointestinal surgery · 2025Article
- Association between platelet‑to‑lymphocyte ratio and serum prostate specific antigen.Molecular and clinical oncology · 2024Article
- Review
- Potential Molecular Biomarkers of Vestibular Schwannoma Growth: Progress and Prospects.Frontiers in oncology · 2021Review
- Predicting Neoadjuvant Chemoradiotherapy Response in Locally Advanced Rectal Cancer Using Tumor-Infiltrating Lymphocytes Density.Journal of inflammation research · 2021Article
- Can the Inflammatory Cell Ratio NLR and PLR be Used as a Reliable Marker in Colon Cancer? A Prospective Study.Euroasian journal of hepato-gastroenterologyArticle
Corrections and comments
- Commented on by
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundPrevious studies have reported the utility of systemic inflammatory markers and CD8+ tumor-infiltrating lymphocyte (TIL) separately in predicting response to chemoradiotherapy (CRT) in rectal cancer; however, the efficacy of combining these markers remains unclear.
objectiveThis study aimed to elucidate the predictive efficacy of systemic inflammatory markers combined with CD8+ TIL density on response to neoadjuvant CRT in locally advanced rectal cancer.
methodsTen systemic inflammatory markers and CD8+ TIL density were assessed in 267 patients with rectal cancer using pretreatment clinical data and biopsy samples. Response to CRT was determined using the Dworak tumor regression grade (TRG), with good responders classified as TRG3-4.
resultsReceiver operating characteristic curve analysis showed high areas under the curve for the lymphocyte-to-C-reactive protein ratio (LCR) and neutrophil × monocyte (N × M) value (0.58 and 0.62, respectively). In the multivariate analysis, LCR, N × M value, and CD8+ TIL density were independently associated with good responders (p = 0.016, 0.005, and 0.002, respectively). Stratified analysis with these three markers showed a positive correlation between TRG3-4 ratio and the number of positive predictive factors (8.2%, 20.0%, 34.2%, and 59.1% in patients with 0, 1, 2, and 3 predictors, respectively). Overall and disease-free survival were significantly worse in patients with zero factors present compared with those with one to three factors present.
conclusionsLCR, N × M value, and CD8+ TIL density are independently associated with response to CRT. Assessing local TIL density along with systemic inflammatory markers may be useful for selecting a multimodal neoadjuvant approach in rectal cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.